Redhill Biopharma Ltd. (RDHL): Price and Financial Metrics


Redhill Biopharma Ltd. (RDHL): $0.88

-0.14 (-13.52%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

RDHL POWR Grades


  • RDHL scores best on the Sentiment dimension, with a Sentiment rank ahead of 84.82% of US stocks.
  • RDHL's strongest trending metric is Quality; it's been moving up over the last 179 days.
  • RDHL ranks lowest in Momentum; there it ranks in the 12th percentile.

RDHL Stock Summary

  • The capital turnover (annual revenue relative to shareholder's equity) for RDHL is 9.66 -- better than 96.83% of US stocks.
  • In terms of volatility of its share price, RDHL is more volatile than 96.72% of stocks we're observing.
  • Shareholder yield, a measure of how much is returned to shareholders via dividends and share repurchases, for RDHL comes in at -53.24% -- higher than that of only 8.43% of stocks in our set.
  • Stocks with similar financial metrics, market capitalization, and price volatility to RedHill Biopharma Ltd are ABST, AZYO, AMRS, HTGM, and ITGR.
  • RDHL's SEC filings can be seen here. And to visit RedHill Biopharma Ltd's official web site, go to www.redhillbio.com.

RDHL Valuation Summary

  • RDHL's price/sales ratio is 5.6; this is 50.66% lower than that of the median Healthcare stock.
  • Over the past 105 months, RDHL's EV/EBIT ratio has gone down 0.9.
  • Over the past 105 months, RDHL's price/sales ratio has gone down 2550.9.

Below are key valuation metrics over time for RDHL.

Stock Date P/S P/B P/E EV/EBIT
RDHL 2021-08-31 5.6 15.9 -5.0 -6.6
RDHL 2021-08-30 4.7 13.6 -4.2 -5.7
RDHL 2021-08-27 4.3 12.2 -3.8 -5.2
RDHL 2021-08-26 4.0 11.5 -3.6 -4.9
RDHL 2021-08-25 3.7 5.8 -3.8 -4.9
RDHL 2021-08-24 3.9 6.1 -4.0 -5.2

RDHL Growth Metrics

    Its 3 year net income to common stockholders growth rate is now at -76.38%.
  • The year over year cash and equivalents growth rate now stands at -6.91%.
  • The 4 year cash and equivalents growth rate now stands at 578.65%.
Over the past 34 months, RDHL's revenue has gone up $78,105,000.

The table below shows RDHL's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-12-31 85.757 -65.047 -97.744
2021-09-30 85.147 -62.895 -97.702
2021-09-30 85.147 -62.895 -97.702
2021-06-30 84.481 -53.041 -94.953
2021-03-31 83.878 -49.172 -81.879
2020-12-31 64.359 -48.579 -76.173

RDHL's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • RDHL has a Quality Grade of D, ranking ahead of 11.33% of graded US stocks.
  • RDHL's asset turnover comes in at 0.437 -- ranking 106th of 681 Pharmaceutical Products stocks.
  • NVAX, OPK, and GBT are the stocks whose asset turnover ratios are most correlated with RDHL.

The table below shows RDHL's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.437 0.505 -0.911
2021-03-31 0.456 0.458 -0.689
2020-12-31 0.391 0.427 -0.623
2020-09-30 0.322 0.392 -0.630
2020-06-30 0.235 0.306 -0.787
2020-03-31 0.073 0.366 -1.186

RDHL Stock Price Chart Interactive Chart >

Price chart for RDHL

RDHL Price/Volume Stats

Current price $0.88 52-week high $11.18
Prev. close $1.02 52-week low $0.62
Day low $0.87 Volume 6,323,500
Day high $1.02 Avg. volume 1,231,867
50-day MA $1.20 Dividend yield N/A
200-day MA $2.78 Market Cap 46.47M

Redhill Biopharma Ltd. (RDHL) Company Bio


RedHill Biopharma Ltd. focuses on the development and acquisition of late clinical-stage, proprietary, and orally-administered drugs for the treatment of inflammatory and gastrointestinal diseases, including gastrointestinal cancers in Israel. The company was founded in 2009 and is based in Tel Aviv, Israel.


RDHL Latest News Stream


Event/Time News Detail
Loading, please wait...

RDHL Latest Social Stream


Loading social stream, please wait...

View Full RDHL Social Stream

Latest RDHL News From Around the Web

Below are the latest news stories about RedHill Biopharma Ltd that investors may wish to consider to help them evaluate RDHL as an investment opportunity.

RedHill Biopharma Announces Record Quarterly Revenues and First Commercial Operations Breakeven

RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today provided a business update for the fourth quarter of 2021, including certain estimated unaudited preliminary financial data.

Yahoo | February 17, 2022

RedHill Biopharma says oral COVID-19 therapy lowered mortality in hospitalized patients

Announcing data from a Phase 2/3 trial for its COVID-19 therapy opaganib, RedHill Biopharma (RDHL -2.4%) said Monday that the oral treatment “significantly reduced” death among hospitalized patients who had previously received standard-of-care (SOC). According to the prespecified mortality analysis, among those who were receiving SOC of remdesivir and corticosteroids,...

Seeking Alpha | February 7, 2022

CLARET ASSET MANAGEMENT Corp Buys Bristol-Myers Squibb Co, Shopify Inc, Hertz Global Holdings ...

Investment company CLARET ASSET MANAGEMENT Corp (Current Portfolio) buys Bristol-Myers Squibb Co, Shopify Inc, Hertz Global Holdings Inc, Newmont Corp, Sangoma Technologies Corp, sells Berkshire Hathaway Inc, Apple Inc, Bank of Montreal, Boeing Co, Bank of Nova Scotia during the 3-months ended 2021Q4, according to the most recent filings of the investment company, CLARET ASSET MANAGEMENT Corp.

Yahoo | February 7, 2022

RedHill Biopharma's Oral Opaganib Reduces Mortality by 70% Given on Top of Remdesivir and Corticosteroids in Severe COVID-19

RedHill Biopharma Ltd. (NASDAQ: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced results from two recently completed prespecified analyses from the oral opaganib (ABC294640)[1] Phase 2/3 study in hospitalized severe COVID-19. The first analysis showed that opaganib significantly reduced mortality when given to patients who received remdesivir and corticosteroids, the best available standard-of-care (SoC) for hospitalized patients. A second analysis furth

Yahoo | February 7, 2022

Henry James International Management Inc. ...

Investment company Henry James International Management Inc. (Current Portfolio) buys Alibaba Group Holding, iShares MSCI Emerging Markets ETF, Materialise NV, EPAM Systems Inc, Endava PLC, sells Core Laboratories NV, Betterware de Mexico SAB de CV, Gazprom PJSC, Piedmont Lithium Inc, Cellectis SA during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Henry James International Management Inc..

Yahoo | January 18, 2022

Read More 'RDHL' Stories Here

RDHL Price Returns

1-mo N/A
3-mo -65.08%
6-mo -65.89%
1-year -87.43%
3-year -86.46%
5-year -89.79%
YTD -65.89%
2021 -68.07%
2020 33.11%
2019 9.37%
2018 7.98%
2017 -50.86%

Continue Researching RDHL

Want to see what other sources are saying about RedHill Biopharma Ltd's financials and stock price? Try the links below:

RedHill Biopharma Ltd (RDHL) Stock Price | Nasdaq
RedHill Biopharma Ltd (RDHL) Stock Quote, History and News - Yahoo Finance
RedHill Biopharma Ltd (RDHL) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.5176 seconds.